Serum transthyretin levels and disease activity in patients with primary Sjögren’s syndrome

Abstract

Background: A strong association has been demonstrated between serum transthyretin (TTR) levels and autoimmune diseases. However, there is limited information regarding the role of serum TTR in patients with primary Sjögren’s syndrome (pSS). Objectives: This study was designed to explore the association between serum TTR and disease activity in patients with pSS. Design: This study was a retrospective observational study. Methods: This study included 84 patients with pSS and 135 age- and sex-matched healthy controls retrospectively, and collected data were analyzed. The European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI) scores were used to assess the disease activity in patients with pSS. Results: Serum TTR levels were significantly lower in patients with pSS than those in healthy controls (181.9 ± 69.2 vs 241.8 ± 48.9 mg/L, p < 0.001). Serum TTR levels were significantly and negatively correlated with ESSDAI ( r = −0.385, p < 0.001) and ClinESSDAI ( r = −0.340, p = 0.002) scores in patients with pSS, respectively. Multivariable linear regression analysis showed that serum TTR was significantly associated with ESSDAI (Beta = −0.248, p = 0.017) and ClinESSDAI (Beta = −0.215, p = 0.036) scores in patients with pSS, respectively. Conclusion: Serum TTR is a potential marker for assessing disease activity in patients with pSS, which may contribute to the clinical management of pSS.